Intellectual Thoughts by Sanjay Panda: Lilly seals a R&D deal with Zydus


Lilly seals a R&D deal with Zydus

Lilly and Zydus established a collaboration to discover and develop potential drug candidates against a novel target, with the research primarily focused on cardiovascular diseases.

Zydus’ role within this covers drug discovery, lead identification and optimisation and conducting preclinical studies and clinical trials up to Phase II human proof-of-concept. In return Lilly will provide expertise and feedback regarding toxicology, ADME (adsorption, distribution, metabolism and excretion), chemistry, biology, clinical and regulatory aspects when deemed necessary to increase the probability of success. Lilly will also supply the chemical starting points.

The deal includes the option for Lilly to license any of the resulting molecules at different stages of development, with Zydus receiving up to $300m (€226m) in milestone payments. Zydus would also receive royalties from any product that reaches commercialisation.

No comments: